Protocol Ledger

NCT06775860 · Phase III · RECRUITING

ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis

Interventional Phase III clinical trial protocol NCT06775860 sponsored by Beijing InnoCare Pharma Tech Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-11-14 Enrollment: 552 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06775860
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)552 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06775860
Protocol FieldVerified Registry Value
NCT IdentifierNCT06775860
Consolidated Lead SponsorBeijing InnoCare Pharma Tech Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment552 participants (ESTIMATED)
Registered Start Date2024-11-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI